REG - Ondine Biomedical - Notice of Interim Results & Investor Presentation

Ondine BiomedicalAnnouncement

19/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250919:nRSS9578Za&default-theme=true

RNS Number : 9578Z  Ondine Biomedical Inc.  19 September 2025

19 September 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Notice of Interim Results and Investor Presentation

Ondine Biomedical Inc. (AIM: OBI) announces that it will publish its
unaudited interim financial results for the period ended 30 June 2025 ("Half
Year Results") on 26 September 2025.

Dr. Nicolas Loebel, President and Chief Technology Officer, and Alan Thomas,
Interim Chief Financial Officer, of the Company, will provide a live
presentation relating to the Half Year Results via Investor Meet Company on 26
September 2025 at 16:30 BST (08:30 Pacific time).

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
25 September 2025, 09:00 BST (01:00 Pacific time), or at any time during the
live presentation.

Investors can sign up to Investor Meet Company for free and add to meet ONDINE
BIOMEDICAL INC. via:

https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor
(https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor)

Investors who already follow ONDINE BIOMEDICAL INC. on the Investor Meet
Company platform will automatically be invited.

 

Enquiries:

 Ondine Biomedical Inc.                                            www.ondinebio.com
 Carolyn Cross, CEO                                                +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Joint Financial Adviser)
 James Harris, Richard Johnson                                     +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Advisor)
 James Steel, Dr. Chris Golden                                     +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                                  +44 (0)77 1000 5910

 

 

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies (also known as 'photodisinfection').
Ondine has a pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of development.

 

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved
for nasal decolonisation in Canada, Australia, Mexico and several other
countries under the name Steriwave(®). In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track status by the
FDA and is currently undergoing clinical trials for regulatory approval.
Products beyond nasal photodisinfection include therapies for a variety of
medical indications such as chronic sinusitis, ventilator-associated
pneumonia, burns and other indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBLGDCBSBDGUI